pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis
Independent Review of Syntholene Facility Confirms World Class Proof-of-Performance, Supports Potential for Cost-Competitive Synthetic Aviation Fuel
QIMC Extends Natural Hydrogen and Helium Seismic Program Across the Temiscamingue Graben into Ontario with 26.8 km New Seismic Line
Independent Review of Syntholene Facility Confirms World Class Proof-of-Performance, Supports Potential for Cost-Competitive Synthetic Aviation Fuel
Edgewater Wireless Brings Growing Semiconductor Momentum and Dual-Use Innovation to Canada's Semiconductor Symposium 2026
